IL2 and cancer: Our lab previously showed that peripheral blood mononuclear cells (PBMCs) obtained from cancer patients pre-IL2 treatment had low levels of ADCC against a neuroblastoma cell line, even in the presence of both anti-GD2 mAb and IL2.